A Phase 1 Dose Escalation and Expansion Study To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Antitumor Activity Of PF-07820435 as Monotherapy and In Combination in Participants With Advanced Solid Tumors
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Principal Investigator
-
Sponsor
Pfizer
Study To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, And Antitumor Activity Of PF-07820435 As Monotherapy And In Combination In Participants With Advanced Solid Tumors